N/A N=231 Mind-body Awareness Training and Brain-computer Interface
Healthy Subjects
Primary: BCI Performance Change From Baseline — 16.87; 7.9 Percent valid correct (PVC) — p=0.003
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
N/A N=31 Evaluation of Binocular Visual Acuity and Refractive Stability in the Alcon Clareon Intraocular Lens
Cataract
Primary: Refractive Stability — 0.03 Diopters (D)
Phase 1 N=28 Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy
Leber's Hereditary Optic Neuropathy
Primary: Number of Treatment Related Adverse Events — 1; 1; 1; 5 Participants
Phase 1 N=63 PAVS in Cardiology
Cardiovascular Diseases
Primary: Step Counts — 48770 steps
N/A N=87 Modulation of the Intestinal Microbiome by a High Protein Diet
Obesity
Primary: Weight Loss (% Change) in Response to Dietary Intervention Change — -3.83; -3.89 percentage weight change from baseline
Phase 1 N=8 Imipenem/Cilastatin/Relebactam PK in ECMO
Sepsis
Primary: Imipenem Clearance — 15.21 Liters per hour
Phase 2 N=59 SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy
Small-cell Lung Cancer
Primary: Adverse Event — 47; 6; 5 participants
N/A N=100 HIS-Purkinje Conduction System Pacing Optimized Trial of Cardiac Resynchronization Therapy
Heart Failure，Congestive · Cardiomyopathies · Left Ventricular Dysfunction
Primary: Primary Endpoint — 12.4; 8.0 percent ejection fraction
Phase 2 N=131 A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
Diabetic Peripheral Neuropathic Pain
Primary: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.70; -1.81 score on a scale
Phase 4 N=60 Self-Assessment Method for Statin Side-effects Or Nocebo
Adverse Effects · Cardiovascular Diseases · Hyperlipidemias
Primary: Mean Symptom Scores Across Statin, Placebo and no Treatment Periods — 16.3; 15.4; 8.0 units on a scale
Phase 2 N=51 Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
Neovascular Age-related Macular Degeneration
Primary: Treatment Emergent Adverse Events (TEAEs) Will be Evaluated for Ocular and Systemic Safety and Tolerability of a Repeat IVT Injection of UBX1325 Compared to Active…
N/A N=58 Maximizing the Impact of Neuroplasticity Using Transcranial Electrical Stimulation Study 1
Transcranial Direct Current Stimulation · Healthy
Primary: Changes in Thalamocortical Functional Connectivity (FC) — 22.7; 20.5; 21.9 arbitrary units
Phase 3 N=1,105 Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
Overactive Bladder
Primary: Change From Baseline at Week 12 in the Average Number of Micturition Episodes Per Day — -2.04; -1.30 Micturitions per day — p=<0.0001
Phase 3 N=106 A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Epithelial Ovarian Cancer · Peritoneal Cancer · Fallopian Tube Cancer
Primary: Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors…